Lead Product(s) : AP1189
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : AP1189
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Melphalan Flufenamide
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2018
Lead Product(s) : Melphalan Flufenamide
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IdeS
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 03, 2016
Lead Product(s) : IdeS
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IdeS
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Uppsala University Hospital | Karolinska Institutet
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 18, 2015
Lead Product(s) : IdeS
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Uppsala University Hospital | Karolinska Institutet
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IdeS
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 25, 2014
Lead Product(s) : IdeS
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Setanaxib
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2013
Lead Product(s) : Setanaxib
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 30, 2012
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable